Intraperitoneal immunization with oligomannose‐coated liposome‐entrapped soluble leishmanial antigen induces antigen‐specific T‐helper type immune response in BALB/c mice through uptake by peritoneal macrophages

Abstract

The present study demonstrates that the intraperitoneal administration of soluble leishmanial antigen (SLA) entrapped in liposomes coated with neoglycolipids containing oligomannose residues (mannopentaose or mannotriose) strongly induces an antigen-specific T-helper type 1 (Th1) immune response in BALB/c mice. In response to in vitro stimulation with SLA, spleen cells from mice that had received oligomannose-coated liposomes encasing SLA (SLA-OML) displayed greater interferon (IFN)-gamma and interleukin (IL)-2 production and lower IL-4 and IL-5 production than spleen cells from mice that had received SLA alone, indicating that the SLA-specific Th1 immune response had predominantly been induced in the mice that had received SLA-OML. After subsequent infection with Leishmania major, mice that had received SLA-OML were effectively protected against the disease, with a predominant production of IFN-gamma. OML were preferentially and rapidly incorporated into peritoneal macrophages, and the transplantation of macrophages containing SLA-OML into the peritoneal cavity also induced protection against L. major infection. Thus, SLA-OML were shown to successfully induce a specific Th1 immune response capable of controlling L. major infection in BALB/c mice through the effective uptake of OML by peritoneal macrophages.

Glycosylation-mediated targeting of carriers

“…In addition, vaccination of peptides by subcutaneous [178] and intraperitoneal [204,205] routes have been studied. Mannosylated liposomes were efficiently taken up by macrophages and/or dendritic cells in various tissues according to each administration route.…”

“…Similarly, encapsulation of various peptides to induce cytotoxic T lymphocytes for vaccination have been investigated [178,204,205].…”

Sustainable inhibition efficacy of liposome-encapsulated nisin on insoluble glucan-biofilm synthesis byStreptococcus mutans

“…Liposomes were prepared as described previously (Shimizu et al, 2007). Phospholipon 90G (2.0 μmol; Lipoid AG, Cham, Switzerland) and phytosphingosine (0.4 μmol; Evonik Goldschmidt GmbH, Essen, Germany) in a solution of chloroform: methanol (2:1, v/v) were placed in a flask and dried by evaporation.…”

Development of Novel Carbohydrate-Coated Liposome-Based Vaccines

“…The therapeutic efficacies of the OMLbased vaccines tested to date are summarized in Table I. A promising result was initially obtained in an animal model of infection by Leishmania major (13). A Th1 immune response is the key event in preventing L. major infection, and in a resistant mouse strain the infection predominantly induces onset of a Th1 immune response that leads to recovery from the infection.…”

“…We have recently developed a new technology for control of diseases such as protozoan infectious diseases, cancer and allergy using oligomannose-coated liposomes (OMLs) as antigen carriers (13)(14)(15)(16). This approach relies on the preferential recognition of oligomannose residues on OMLs by APCs with APC-specific mannose-binding lectin receptors, and subsequent uptake of OMLs and presentation of antigens encased in the OMLs on MHC class I and class II molecules (17).…”